Latest articles and price-sensitive announcements with AI sentiment classification.
A sharp fall can make investors cautious, but it can also create opportunity when the long-term business remains strong. The post Down 30%, should I buy ResMed shares now? appeared first on The Motley Fool Australia.
Highlights ResMed (ASX:RMD) has been pressured by concerns that GLP-1 drugs could reduce sleep apnoea device demand. Real-world evidence suggests patients often use GLP-1 therapies alongside CPAP treatment. Sentiment across ASX healthcare is shifting as fears are reassessed against actual clinical behaviour. ResMed has been pressured by GLP-1 fears, but real-world data shows combined therapy use is common. This challenges disruption concerns and reshapes sentiment across ASX healthcare ...
Highlights ResMed continues to attract attention as global healthcare demand and sleep disorder treatments remain structurally relevant. Valuation discussions highlight the tension between long-term growth expectations and recent market re-rating. Sector rotation in the [ASX 200] is shaping sentiment across major healthcare names including ResMed. ResMed continues to attract market attention as healthcare trends evolve, with global demand, digital health growth and valuation debates sha...
Highlights ResMed shares declined despite broader market strength as concerns around weight-loss drugs resurfaced. Market attention remains focused on the long-term impact of obesity treatments on sleep apnea therapies. The company continues to report strong operational performance while expanding into adjacent healthcare segments. ResMed shares remain under pressure as investors assess whether obesity treatments could reshape sleep apnea markets, despite the company continuing to deliver str...
A leading analyst provides his outlook for the beaten-down ResMed share price. The post Down 28% in a year, should I buy the dip on Resmed shares right now? appeared first on The Motley Fool Australia.
ResMed (ASX:RMD) Q3 Results 2026: Is the ASX Healthcare Stock Back on Track? Kalkine
ResMed (ASX:RMD) Falls Despite Earnings Beat: Buy the Dip? Stocks Down Under
The sleep disorder treatment company has released its third-quarter update this morning. The post What's going on with ResMed shares today? appeared first on The Motley Fool Australia.
other announcement
Highlights Strong global footprint across healthcare solutions Balanced mix of hardware and software offerings Financial position reflects stability and flexibility ResMed continues to attract attention due to its expanding healthcare ecosystem, steady revenue trajectory, and resilient financial structure, making it a closely watched name within the broader Australian market landscape. Understanding the Momentum Behind (RMD) The keyword Are Resmed CDI (ASX:RMD) shares good value in 2026...
other announcement
Highlights Strong revenue expansion supports long-term growth narrative Balanced financial structure with solid cash position Valuation levels appear below historical trend ResMed CDI (RMD) continues to demonstrate steady business momentum, supported by global demand in healthcare technology. A closer look at financial metrics reveals how growth, margins, and valuation trends shape its current market position. Understanding ResMed CDI (RMD) Share Value in 2026 The keyword Resmed CDI (AS...
other announcement
other announcement
Motley Fool
Kalkine
ASX
Google News